Atypical causes of cholestasis

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9418-9426

  Nguyen, Ken D ^a   Sundaram, Vinay ^a   Ayoub, Walid S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Alagille syndrome; Benign recurrent intrahepatic cholestasis; Biliary atresia; Cholestasis; Drug induced liver injury; Progressive familial intrahepatic cholestasis; Total parenteral nutrition

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOTETAN; CEFTRIAXONE; CELECOXIB; CIPROFLOXACIN; COTRIMOXAZOLE; DICLOFENAC; DOXYCYCLINE; FIALURIDINE; FLUCONAZOLE; ISONIAZID; LEVOFLOXACIN; METHYLDOPA; MINOCYCLINE; NEVIRAPINE; NITROFURANTOIN; ORAL CONTRACEPTIVE AGENT; OXACILLIN; PARACETAMOL; PHENYTOIN; PIPERACILLIN; PROGESTERONE; TELITHROMYCIN; TERBINAFINE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID;

ALAGILLE SYNDROME; ARTICLE; BILE DUCT ATRESIA; BILE DUCT DISEASE; CHOLESTASIS; EARLY DIAGNOSIS; FAMILIAL DISEASE; HEALTH CARE ORGANIZATION; HERBAL MEDICINE; HUMAN; INCIDENCE; INTRAHEPATIC CHOLESTASIS; INTRAHEPATIC CHOLESTASIS OF PREGNANCY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER ISCHEMIA; LIVER TOXICITY; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PORTOENTEROSTOMY; PRACTICE GUIDELINE; PREGNANCY DISORDER; PREGNANT WOMAN; PROGNOSIS; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS; RECURRENT DISEASE; RISK FACTOR; SEPSIS; TOTAL PARENTERAL NUTRITION; TOXIC HEPATITIS; ADVERSE EFFECTS; CHOLESTASIS, INTRAHEPATIC; COMPLICATION; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEREDITY; MALE; PEDIGREE; PHENOTYPE; PREGNANCY; PREGNANCY COMPLICATIONS;

ALAGILLE SYNDROME; BILIARY ATRESIA; CHOLESTASIS; CHOLESTASIS, INTRAHEPATIC; DRUG-INDUCED LIVER INJURY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HUMANS; MALE; PARENTERAL NUTRITION, TOTAL; PEDIGREE; PHENOTYPE; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS; RECURRENCE; RISK FACTORS; SEPSIS;

EID: 84908888872     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9418     Document Type: Article

References (90)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267 [PMID: 19501929 DOI: 10.1016/j.jhep.2009.04.009]
2. Summerskill WH, Walshe JM. Benign recurrent intrahepatic "obstructive" jaundice. Lancet 1959; 2: 686-690 [PMID: 13835689]
3. De Koning TJ, Sandkuijl LA, De Schryver JE, Hennekam EA, Beemer FA, Houwen RH. Autosomal-recessive inheritance of benign recurrent intrahepatic cholestasis. Am J Med Genet 1995; 57: 479-482 [PMID: 7677155 DOI: 10.1002/ajmg.1320570324]
4. de Pagter AG, van Berge Henegouwen GP, ten Bokkel Huinink JA, Brandt KH. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology 1976; 71: 202-207 [PMID: 939378]
5. Schapiro RH, Isselbacher KJ. Benign recurrent intrahepatic cholestasis. N Engl J Med 1963; 268: 708-711 [PMID: 13976702 DOI: 10.1056/NEJM196303282681305]
6. Tygstrup N. Intermittent possibly familial intrahepatic cholestatic jaundice. Lancet 1960; 1: 1171-1172 [PMID: 13840084]
7. Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis 2004; 8: 133-49, vii [PMID: 15062197 DOI: 10.1016/S1089-3261(03)00133-8]
8. Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 2012; 36 Suppl 1: S26-S35 [PMID: 23141890 DOI: 10.1016/S2210-7401(12)70018-9]
9. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, Bernard O, Jacquemin E. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology 2010; 51: 1645-1655 [PMID: 20232290 DOI: 10.1002/hep.23539]
10. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009; 4: 1 [PMID: 19133130 DOI: 10.1186/1750-1172-4-1]
11. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010; 30: 134-146 [PMID: 20422496 DOI: 10.1055/s-0030-1253223]
12. Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, Rudi de Waart D, Hoek FJ, Vreeling H, Hoeben KA, van Marle J, Pawlikowska L, Bull LN, Hofmann AF, Knisely AS, Oude Elferink RP. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 2006; 44: 195-204 [PMID: 16799980 DOI: 10.1002/hep.21212]
13. Alagille D, Estrada A, Hadchouel M, Gautier M, Odièvre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987; 110: 195-200 [PMID: 3806290]
14. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M, Trask BJ, Kuo WL, Cochran J, Costa T, Pierpont ME, Rand EB, Piccoli DA, Hood L, Spinner NB. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997; 16: 243-251 [PMID: 9207788 DOI: 10.1038/ng0797-243]
15. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, Piccoli DA, Meltzer PS, Spinner NB, Collins FS, Chandrasekharappa SC. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997; 16: 235-242 [PMID: 9207787 DOI: 10.1038/ng0797-235]
16. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 2006; 79: 169-173 [PMID: 16773578 DOI: 10.1086/505332]
17. Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2012; 20: 251-257 [PMID: 21934706 DOI: 10.1038/ejhg.2011.181]
18. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999; 29: 822-829 [PMID: 10051485 DOI: 10.1002/hep.510290331]
19. McElhinney DB, Krantz ID, Bason L, Piccoli DA, Emerick KM, Spinner NB, Goldmuntz E. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation 2002; 106: 2567-2574 [PMID: 12427653]
20. Kamath BM, Schwarz KB, Hadzić N. Alagille syndrome and liver transplantation. J Pediatr Gastroenterol Nutr 2010; 50: 11-15 [PMID: 19949348 DOI: 10.1097/MPG.0b013e3181c1601f]
21. Kasahara M, Kiuchi T, Inomata Y, Uryuhara K, Sakamoto S, Ito T, Fujimoto Y, Ogura Y, Oike F, Tanaka K. Living-related liver transplantation for Alagille syndrome. Transplantation 2003; 75: 2147-2150 [PMID: 12829928 DOI: 10.1097/01. TP.0000066804.33006.17]
22. Caponcelli E, Knisely AS, Davenport M. Cystic biliary atresia: an etiologic and prognostic subgroup. J Pediatr Surg 2008; 43: 1619-1624 [PMID: 18778995 DOI: 10.1016/j.jpedsurg.2007.12.058]
23. Davenport M, Tizzard SA, Underhill J, Mieli-Vergani G, Portmann B, Hadzić N. The biliary atresia splenic malformation syndrome: a 28-year single-center retrospective study. J Pediatr 2006; 149: 393-400 [PMID: 16939755 DOI: 10.1016/j.jpeds.2006.05.030]
24. Fischler B, Haglund B, Hjern A. A population-based study on the incidence and possible pre- and perinatal etiologic risk factors of biliary atresia. J Pediatr 2002; 141: 217-222 [PMID: 12183717 DOI: 10.1067/mpd.2002.126001]
25. Chardot C, Carton M, Spire-Bendelac N, Le Pommelet C, Golmard JL, Auvert B. Epidemiology of biliary atresia in France: a national study 1986-96. J Hepatol 1999; 31: 1006-1013 [PMID: 10604573]
26. Yoon PW, Bresee JS, Olney RS, James LM, Khoury MJ. Epidemiology of biliary atresia: a population-based study. Pediatrics 1997; 99: 376-382 [PMID: 9041292]
27. Chen SM, Chang MH, Du JC, Lin CC, Chen AC, Lee HC, Lau BH, Yang YJ, Wu TC, Chu CH, Lai MW, Chen HL. Screening for biliary atresia by infant stool color card in Taiwan. Pediatrics 2006; 117: 1147-1154 [PMID: 16585309 DOI: 10.1542/peds.2005-1267]
28. Nio M, Ohi R, Miyano T, Saeki M, Shiraki K, Tanaka K. Fiveand 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry. J Pediatr Surg 2003; 38: 997-1000 [PMID: 12861525]
29. Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet 2009; 374: 1704-1713 [PMID: 19914515 DOI: 10.1016/S0140-6736(09)60946-6]
30. de Vries W, Homan-Van der Veen J, Hulscher JB, Hoekstra-Weebers JE, Houwen RH, Verkade HJ. Twenty-year transplant-free survival rate among patients with biliary atresia. Clin Gastroenterol Hepatol 2011; 9: 1086-1091 [PMID: 21820397 DOI: 10.1016/j.cgh.2011.07.024]
31. Lykavieris P, Chardot C, Sokhn M, Gauthier F, Valayer J, Bernard O. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology 2005; 41: 366-371 [PMID: 15660386 DOI: 10.1002/hep.20547]
32. Davenport M, Ong E, Sharif K, Alizai N, McClean P, Hadzic N, Kelly DA. Biliary atresia in England and Wales: results of centralization and new benchmark. J Pediatr Surg 2011; 46: 1689-1694 [PMID: 21929975 DOI: 10.1016/j.jpedsurg.2011.04.013]
33. Wildhaber BE, Majno P, Mayr J, Zachariou Z, Hohlfeld J, Schwoebel M, Kistler W, Meuli M, Le Coultre C, Mentha G, Belli D, Chardot C. Biliary atresia: Swiss national study, 1994-2004. J Pediatr Gastroenterol Nutr 2008; 46: 299-307 [PMID: 18376248 DOI: 10.1097/MPG.0b013e3181633562]
34. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology 2007; 45: 230-241 [PMID: 17187426 DOI: 10.1002/hep.21480]
35. Bolder U, Ton-Nu HT, Schteingart CD, Frick E, Hofmann AF. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 1997; 112: 214-225 [PMID: 8978362]
36. Green RM, Beier D, Gollan JL. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 1996; 111: 193-198 [PMID: 8698199]
37. Hojo M, Sano N, Takikawa H. Effects of lipopolysaccharide on the biliary excretion of bile acids and organic anions in rats. J Gastroenterol Hepatol 2003; 18: 815-821 [PMID: 12795754]
38. Roelofsen H, van der Veere CN, Ottenhoff R, Schoemaker B, Jansen PL, Oude Elferink RP. Decreased bilirubin transport in the perfused liver of endotoxemic rats. Gastroenterology 1994; 107: 1075-1084 [PMID: 7926459]
39. Bätge B, Filejski W, Kurowski V, Klüter H, Djonlagic H. Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment. Intensive Care Med 1992; 18: 488-490 [PMID: 1289375]
40. Smith LD. Virulence factors of Clostridium perfringens. Rev Infect Dis 1979; 1: 254-262 [PMID: 232935]
41. Berkowitz FE. Hemolysis and infection: categories and mechanisms of their interrelationship. Rev Infect Dis 1991; 13: 1151-1162 [PMID: 1775848]
42. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2009; 73-79 [PMID: 20008184 DOI: 10.1182/asheducation-2009.1.73]
43. Guglielmi FW, Regano N, Mazzuoli S, Fregnan S, Leogrande G, Guglielmi A, Merli M, Pironi L, Penco JM, Francavilla A. Cholestasis induced by total parenteral nutrition. Clin Liver Dis 2008; 12: 97-110, viii [PMID: 18242499 DOI: 10.1016/j.cld.2007.11.004]
44. O'Brien DP, Nelson LA, Kemp CJ, Williams JL, Wang Q, Erwin CR, Hasselgren PO, Warner BW. Intestinal permeability and bacterial translocation are uncoupled after small bowel resection. J Pediatr Surg 2002; 37: 390-394 [PMID: 11877654]
45. Allardyce DB. Cholestasis caused by lipid emulsions. Surg Gynecol Obstet 1982; 154: 641-647 [PMID: 7071699]
46. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132: 525-532 [PMID: 10744588]
47. Jeejeebhoy KN. Management of short bowel syndrome: avoidance of total parenteral nutrition. Gastroenterology 2006; 130: S60-S66 [PMID: 16473074 DOI: 10.1053/j.gastro.2005.10.065]
48. Fell JM, Reynolds AP, Meadows N, Khan K, Long SG, Quaghebeur G, Taylor WJ, Milla PJ. Manganese toxicity in children receiving long-term parenteral nutrition. Lancet 1996; 347: 1218-1221 [PMID: 8622451]
49. Craig RM, Neumann T, Jeejeebhoy KN, Yokoo H. Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition. Gastroenterology 1980; 79: 131-137 [PMID: 6769748]
50. Stanko RT, Nathan G, Mendelow H, Adibi SA. Development of hepatic cholestasis and fibrosis in patients with massive loss of intestine supported by prolonged parenteral nutrition. Gastroenterology 1987; 92: 197-202 [PMID: 3096806]
51. Capron JP, Gineston JL, Herve MA, Braillon A. Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet 1983; 1: 446-447 [PMID: 6131169]
52. Kubota A, Okada A, Imura K, Kawahara H, Nezu R, Kamata S, Takagi Y. The effect of metronidazole on TPN-associated liver dysfunction in neonates. J Pediatr Surg 1990; 25: 618-621 [PMID: 2113577]
53. Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 2000; 33: 1012-1021 [PMID: 11131439]
54. Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007; 2: 26 [PMID: 17535422 DOI: 10.1186/1750-1172-2-26]
55. Riely CA, Bacq Y. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 2004; 8: 167-176 [PMID: 15062199 DOI: 10.1016/S1089-3261(03)00131-4]
56. Reyes H, Gonzalez MC, Ribalta J, Aburto H, Matus C, Schramm G, Katz R, Medina E. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med 1978; 88: 487-493 [PMID: 637428]
57. Hay JE. Liver disease in pregnancy. Hepatology 2008; 47: 1067-1076 [PMID: 18265410 DOI: 10.1002/hep.22130]
58. Bacq Y, Gendrot C, Perrotin F, Lefrou L, Chrétien S, Vie-Buret V, Brechot MC, Andres CR. ABCB4 gene mutations and single-nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy. J Med Genet 2009; 46: 711-715 [PMID: 19584064 DOI: 10.1136/jmg.2009.067397]
59. Dixon PH, van Mil SW, Chambers J, Strautnieks S, Thompson RJ, Lammert F, Kubitz R, Keitel V, Glantz A, Mattsson LA, Marschall HU, Molokhia M, Moore GE, Linton KJ, Williamson C. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009; 58: 537-544 [PMID: 18987030 DOI: 10.1136/gut.2008.159541]
60. Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Variola A, Tommasi AM, Marchesoni D, Braghin C, Mazzella G. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment Pharmacol Ther 2006; 23: 1649-1653 [PMID: 16696816 DOI: 10.1111/j.1365-2036.2006.02869.x]
61. Lucena JF, Herrero JI, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, Sola J, Herraiz M, Medina JF, Prieto J. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 2003; 124: 1037-1042 [PMID: 12671900 DOI: 10.1053/gast.2003.50144]
62. Wasmuth HE, Glantz A, Keppeler H, Simon E, Bartz C, Rath W, Mattsson LA, Marschall HU, Lammert F. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 2007; 56: 265-270 [PMID: 16891356 DOI: 10.1136/gut.2006.092742]
63. Brites D. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Ann Hepatol 2002; 1: 20-28 [PMID: 15114292]
64. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40: 467-474 [PMID: 15368452 DOI: 10.1002/hep.20336]
65. Lee RH, Kwok KM, Ingles S, Wilson ML, Mullin P, Incerpi M, Pathak B, Goodwin TM. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. Am J Perinatol 2008; 25: 341-345 [PMID: 18509787 DOI: 10.1055/s-2008-1078756]
66. Palma J, Reyes H, Ribalta J, Hernández I, Sandoval L, Almuna R, Liepins J, Lira F, Sedano M, Silva O, Tohá D, Silva JJ. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27: 1022-1028 [PMID: 9453428]
67. Williamson C, Hems LM, Goulis DG, Walker I, Chambers J, Donaldson O, Swiet M, Johnston DG. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG 2004; 111: 676-681 [PMID: 15198757 DOI: 10.1111/j.1471-0528.2004.00167.x]
68. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014; 59: 1482-1491 [PMID: 23857305 DOI: 10.1002/hep.26617]
69. Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T, Nicastri PL, Locatelli A, Floreani A, Hernandez I, Di Martino V. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012; 143: 1492-1501 [PMID: 22892336 DOI: 10.1053/j.gastro.2012.08.004]
70. Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005; 42: 1399-1405 [PMID: 16317669 DOI: 10.1002/hep.20952]
71. Roncaglia N, Locatelli A, Arreghini A, Assi F, Cameroni I, Pezzullo JC, Ghidini A. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004; 111: 17-21 [PMID: 14687046]
72. Mazzella G, Rizzo N, Azzaroli F, Simoni P, Bovicelli L, Miracolo A, Simonazzi G, Colecchia A, Nigro G, Mwangemi C, Festi D, Roda E. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 2001; 33: 504-508 [PMID: 11230728 DOI: 10.1053/jhep.2001.22647]
73. Binder T, Salaj P, Zima T, Vítek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006; 34: 383-391 [PMID: 16965225 DOI: 10.1515/JPM.2006.077]
74. Marschall HU, Wikström Shemer E, Ludvigsson JF, Stephansson O. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. Hepatology 2013; 58: 1385-1391 [PMID: 23564560 DOI: 10.1002/hep.26444]
75. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954 [PMID: 12484709]
76. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485 [PMID: 12890847 DOI: 10.1056/NEJMra021844]
77. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521 [PMID: 16083708 DOI: 10.1016/j.gastro.2005.05.006]
78. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489 [PMID: 16025496 DOI: 10.1002/hep.20800]
79. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-125, 1419-125, quiz 1419-125, [PMID: 23419359 DOI: 10.1053/j.gastro.2013.02.006]
80. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-134, 1924-134, [PMID: 18955056 DOI: 10.1053/j.gastro.2008.09.011]
81. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of druginduced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455 [PMID: 12143055 DOI: 10.1053/jhep.2002.34857]
82. Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, Baik GH, Kim JB, Kweon YO, Kim BI, Kim SH, Kim IH, Kim JH, Nam SW, Paik YH, Suh JI, Sohn JH, Ahn BM, Um SH, Lee HJ, Cho M, Jang MK, Choi SK, Hwang SG, Sung HT, Choi JY, Han KH. A prospective nationwide study of druginduced liver injury in Korea. Am J Gastroenterol 2012; 107: 1380-1387 [PMID: 22733303 DOI: 10.1038/ajg.2012.138]
83. Ghabril M, Fontana R, Rockey D, Jiezhun G, Chalasani N. Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol 2013; 47: 553-558 [PMID: 23388845 DOI: 10.1097/MCG.0b013e318276bf00]
84. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 2011; 53: 1377-1387 [PMID: 21480339 DOI: 10.1002/hep.24229]
85. Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with druginduced liver injury. Aliment Pharmacol Ther 2007; 25: 1411-1421 [PMID: 17539980 DOI: 10.1111/j.1365-2036.2007.03330.x]
86. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53: 1049-1053 [PMID: 20800921 DOI: 10.1016/j.jhep.2010.05.033]
87. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK. Susceptibility to amoxicillinclavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338-347 [PMID: 21570397 DOI: 10.1053/j.gastro.2011.04.001]
88. Reuben A. Hy's law. Hepatology 2004; 39: 574-578 [PMID: 14768020 DOI: 10.1002/hep.20081]
89. Bjornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis 2013; 17: 191-209 [PMID: 23540497 DOI: 10.1016/j.cld.2012.11.002]
90. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10: 1018-1023 [PMID: 15390328 DOI: 10.1002/lt.20204]